Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Number of clinical trials in Finland falls in 2007

This article was originally published in Scrip

Executive Summary

The number of clinical trials conducted in Finland last year fell to 459 from above 500 in 2006, which was an “exceptionally high” number, says Pharma Industry Finland, the national association. One quarter (115) of them involved medicines for CNS disorders, followed by 104 trials for cancer and substances modulating the immune system response. 175 new trials were initiated in 2007 which was nearly an average figure. The number of patients enrolled increased by around 20% to 48,000, with half of them taking part in Phase III trials and almost 40% in Phase IV trials. The majority (80%) were involved in vaccine trials. In the six years to 2007, clinical trials of vaccines prevailed over other products, with seven to 19 studies being conducted in this group every year. Children participated in those of rotavirus, varicella, influenza and human papillomavirus vaccines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031128

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel